Q-omics provides the consensus-scored LINC01876 profile across patient tissues and cancer cell-line models. LINC01876 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC01876 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, LINC01876 RNA expression shows 14,174 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, HNSC, and THYM as cancer lineages where LINC01876 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01876 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01876 survival associations across molecular data types. LINC01876 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01876 RNA expression–survival associations across cancer types. High LINC01876 expression shows unfavorable associations in KIRP and THCA, but favorable associations in SKCM, READ, UCS and MESO. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC01876 RNA expression.
This table summarizes LINC01876 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01876. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01876 shows higher tumor expression in HNSC, LUAD, LUSC, STAD, LIHC and BLCA. The HNSC box plot shows higher LINC01876 RNA expression in tumor versus normal tissue (log2 FC = +0.294, t-test p = .002).
This table shows molecular features associated with LINC01876 in patient tissues and cancer cell lines. In patient samples, LINC01876 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
